Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 6/20 | 0.71 |
| ▸ | NT5E | P21589 | 3/20 | 0.55 |
| ▸ | AHCY | P23526 | 2/20 | 0.50 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.47 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.46 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.45 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.45 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11427985 | 0.92 | PDE2A (0.64) | PDE2ANT5EAHCYHSPA5HTR1A | |
| SCHEMBL5961364 | 0.92 | PDE2A (0.64) | PDE2ANT5EAHCYHSPA5HTR1A | |
| SCHEMBL14428965 | 0.89 | PDE2A (0.59) | PDE2ANT5EAHCYHSPA5ADORA1 | |
| SCHEMBL14429257 | 0.89 | PDE2A (0.59) | PDE2ANT5EAHCYHSPA5ADORA1 | |
| SCHEMBL14429057 | 0.89 | PDE2A (0.59) | PDE2ANT5EAHCYHSPA5HTR1A | |
| SCHEMBL20096659 | 0.81 | AHCY (0.55) | PDE2ANT5EAHCYADORA1P2RY12 | |
| SCHEMBL622588 | 0.81 | ADORA1 (0.69) | PDE2AAHCYHSPA5ADORA1DOT1L | |
| SCHEMBL750344 | 0.81 | PDE2A (0.72) | PDE2ANT5EHTR1AADORA1 | |
| SCHEMBL14429137 | 0.81 | PDE2A (0.51) | PDE2ANT5EAHCYHSPA5HTR1A | |
| SCHEMBL14440633 | 0.80 | EHMT1 (0.52) | PDE2ANT5EAHCYADORA1DOT1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185063-A1 | Seven-membered ring nucleosides | IDENIX PHARMACEUTICALS, INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185063-A1 | Seven-membered ring nucleosides | NSUN2, NSUN3, HAVCR2 | PDE2A 3198/4885NT5E 158/4885AHCY 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.